Kenneth R. McCurry

Kenneth R. McCurry

Auto-generated profile, based on publicly available information

Kenneth R. McCurry

Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic Research, Cleveland, Ohio, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
DRDirk Van Raemdonck
Dirk Van Raemdonck
SKShaf Keshavjee
Shaf Keshavjee
BLBronwyn Levvey
Bronwyn Levvey
WCWida S. Cherikh
Wida S. Cherikh
GSGreg Snell
Greg Snell
MCMarcelo Cypel
Marcelo Cypel

26 March 2009 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
KMK. R. McCurry
K. R. McCurry
TST. H. Shearon
T. H. Shearon
LEL. B. Edwards
L. B. Edwards
KCK. M. Chan
K. M. Chan
SSS. C. Sweet
S. C. Sweet
SMS. Murray
S. Murray
This article highlights trends and changes in lung and heart‐lung transplantation in the United States from 1998 to 2007. The most significant change over the last decade was implementation of the Lung Allocation Score (LAS) allocation system in May 2005. Subsequently, the number of active wait‐listed lung candidates declined 54% from pre‐LAS (2004) levels to the end of 2007; there was also a reduction in median waiting time, from 792 days in 2004 to 141 days in 2007. The number of lung transplants performed yearly increased through the decade to a peak of 1 465 in 2007; the greatest single year increase occurred in 2005. Despite candidates with increasingly higher LAS scores being transplanted in the LAS era, recipient death rates have remained relatively stable since 2003 and better than in previous years. Idiopathic pulmonary fibrosis became the most common diagnosis group to receive a lung transplant in 2007 while emphysema was the most common diagnosis in previous years. The number of retransplants and transplants in those aged ≥65 performed yearly have increased significantly since 1998, up 295% and 643%, respectively. A decreasing percentage of lung transplant recipients are children (3.5% in 2007, n = 51). With LAS refinement ongoing, monitoring of future impact is warranted.

1 January 2019 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
HNHiromichi Niikawa
Hiromichi Niikawa
TOToshihiro Okamoto
Toshihiro Okamoto
KAKamal S. Ayyat
Kamal S. Ayyat
YIYoshifumi Itoda
Yoshifumi Itoda
CFCarol F. Farver
Carol F. Farver
KMKenneth R. McCurry
Kenneth R. McCurry

20 May 2016 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
PDF file
TOToshihiro Okamoto
Toshihiro Okamoto
DWDavid Wheeler
David Wheeler
QLQiang Liu
Qiang Liu
CQCristiano Quintini
Cristiano Quintini
JHJ. Steven Hata
J. Steven Hata
KMKenneth R. McCurry
Kenneth R. McCurry

27 September 2012 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
RSR. Sugimoto
R. Sugimoto
TOT. Okamoto
T. Okamoto
ANA. Nakao
A. Nakao
JZJ. Zhan
J. Zhan
YWY. Wang
Y. Wang
KMK. R. McCurry
K. R. McCurry
Ischemia/reperfusion injury (IRI) is the most common cause of early mortality following lung transplantation (LTx). We hypothesized that nitrite, an endogenous source of nitric oxide (NO), may protect lung grafts from IRI. Rat lung grafts were stored in preservation solution at 4°C for 6 hours. Both grafts and recipients were treated with nitrite. Nitrite treatment was associated with significantly higher levels of tissue oxygenation, lower levels of cytokines and neutrophil/macrophage infiltration, lower myeloperoxidase activity, reduced oxidative injury and increased cGMP levels in grafts than in the controls. Treatment with either a nitric oxide scavenger or a soluble guanylyl cyclase (sGC) inhibitor diminished the beneficial effects of nitrite and decreased cGMP concentrations. These results suggest that nitric oxide, generated from nitrite, is the molecule responsible for the effects of nitrite via the nitric oxide/sGC/cGMP pathway. Allopurinol, a xanthine oxidoreductase (XOR) inhibitor, abrogated the protective effects of nitrite, suggesting that XOR is a key enzyme in the conversion of nitrite to nitric oxide. In vitro experiments demonstrated that nitrite prevented apoptosis in pulmonary endothelial cells. Nitrite also exhibits longer survival rate in recipients than control. In conclusion, nitrite inhibits lung IRI following cold preservation and had higher survival rate in LTx model.

1 November 2020 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
KAKamal S. Ayyat
Kamal S. Ayyat
TOToshihiro Okamoto
Toshihiro Okamoto
HNHiromichi Niikawa
Hiromichi Niikawa
ISIchiro Sakanoue
Ichiro Sakanoue
SDSiddharth Dugar
Siddharth Dugar
KMKenneth R. McCurry
Kenneth R. McCurry